These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25652048)

  • 21. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma.
    Vercellino L; Montravers F; de Parades V; Huchet V; Kerrou K; Bauer P; Touboul E; Talbot JN
    Int J Colorectal Dis; 2011 Feb; 26(2):201-10. PubMed ID: 21061012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
    Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
    Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: the role of US, MRI and FDG-PET/TC scans to assess residual neck disease.
    Pellini R; Manciocco V; Turri-Zanoni M; Vidiri A; Sanguineti G; Marucci L; Sciuto R; Covello R; Sperduti I; Kayal R; Anelli V; Pichi B; Mercante G; Spriano G
    J Craniomaxillofac Surg; 2014 Dec; 42(8):1834-9. PubMed ID: 25150165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT.
    Brown PJ; Zhong J; Frood R; Currie S; Gilbert A; Appelt AL; Sebag-Montefiore D; Scarsbrook A
    Eur J Nucl Med Mol Imaging; 2019 Dec; 46(13):2790-2799. PubMed ID: 31482428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? A prospective analysis.
    Cacicedo J; Fernandez I; Del Hoyo O; Dolado A; Gómez-Suarez J; Hortelano E; Sancho A; Pijoan JI; Alvarez J; Espinosa JM; Gaafar A; Bilbao P
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1378-89. PubMed ID: 25952280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
    Mohammadkhani Shali S; Schmitt V; Behrendt FF; Winz OH; Heinzel A; Mottaghy FM; Eble MJ; Verburg FA
    Eur J Radiol; 2016 Aug; 85(8):1390-4. PubMed ID: 27423677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.
    Gómez-Caro A; Boada M; Cabañas M; Sanchez M; Arguis P; Lomeña F; Ramirez J; Molins L
    Eur J Cardiothorac Surg; 2012 Jul; 42(1):93-100; discussion 100. PubMed ID: 22290911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
    Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
    J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study.
    Lonneux M; Hamoir M; Reychler H; Maingon P; Duvillard C; Calais G; Bridji B; Digue L; Toubeau M; Grégoire V
    J Clin Oncol; 2010 Mar; 28(7):1190-5. PubMed ID: 20124179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic utility of squamous cell carcinoma antigen in carcinoma of the cervix: association with pre- and posttreatment FDG-PET.
    Olsen JR; Dehdashti F; Siegel BA; Zighelboim I; Grigsby PW; Schwarz JK
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):772-7. PubMed ID: 20888130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma.
    Iagaru A; Kundu R; Jadvar H; Nagle D
    Hell J Nucl Med; 2009; 12(1):26-9. PubMed ID: 19330178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre- and post-treatment FDG PET-CT as a predictor of patient outcomes in anal squamous cell carcinoma: A systematic review and meta-analysis.
    Mac Curtain BM; Qian W; Bell J; O'Mahony A; Temperly HC; Ng ZQ
    J Med Imaging Radiat Oncol; 2023 Sep; 67(6):634-646. PubMed ID: 37573606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
    J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG-PET/CT in the evaluation of anal carcinoma.
    Cotter SE; Grigsby PW; Siegel BA; Dehdashti F; Malyapa RS; Fleshman JW; Birnbaum EH; Wang X; Abbey E; Tan B; Kodner IJ; Hunt SR; Lowney JK; Mutch MG; Dietz DW; Myerson RJ
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):720-5. PubMed ID: 16626889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of FDG-PET/CT on the management of head and neck tumours: the radiotherapist's perspective.
    Dietl B; Marienhagen J; Kühnel T; Schreyer A; Kölbl O
    Oral Oncol; 2008 May; 44(5):504-8. PubMed ID: 17826307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy.
    Day FL; Link E; Ngan S; Leong T; Moodie K; Lynch C; Michael M; Winton Ed; Hogg A; Hicks RJ; Heriot A
    Br J Cancer; 2011 Aug; 105(4):498-504. PubMed ID: 21792197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
    Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
    J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer.
    Teagle AR; Gilbert DC; Jones JR; Burkill GJ; McKinna F; Dizdarevic S
    Nucl Med Commun; 2016 Oct; 37(10):1038-45. PubMed ID: 27341410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer.
    Mistrangelo M; Pelosi E; Bellò M; Castellano I; Cassoni P; Ricardi U; Munoz F; Racca P; Contu V; Beltramo G; Morino M; Mussa A
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):73-8. PubMed ID: 19632066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.